FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why

The FDA placed a clinical hold  on DiaMedica Therapeutics Inc's  (NASDAQ: DMAC ) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ischemic stroke patients.  The clinical hold was initiated following the company's pause in patient enrollment and submission of three serious adverse event reports related to clinically significant transient hypotension (low blood pressure) occurring shortly after initiating the ... Full story available on Benzinga.com